# SouthernBiotech <u> </u>



# Rat Anti-Mouse CD71

Cat. No.	Format	Size
1720-01	Purified (UNLB)	0.5 mg
1720-02	Fluorescein (FITC)	0.5 mg
1720-08	Biotin (BIOT)	0.5 mg
1720-09	R-phycoerythrin (PE)	0.1 mg
1720-14	Low Endotoxin, Azide-Free (LE/AF)	0.5 mg



Mouse pre-B cell line 18-81 was stained with Rat Anti-Mouse CD71-PE (SB Cat. No. 1720-09).

#### **Overview**

Clone	RI7217
Isotype	Rat (BDIX) IgG <sub>2a</sub> ĸ
Immunogen	DMSO induced Friend erythroleukemia 745.6
Specificity	Mouse CD71; Mr 95 kDa
Alternate Name(s)	T9, transferrin receptor, TfR

## Description

CD71, a type II transmembrane glycoprotein expressed on the cell surface as a homodimer, is the transferrin receptor. It is essential for the growth of normal and neoplastic cells. It is expressed at low levels on resting B and T lymphocytes but is upregulated during responses to antigens and mitogens presumably reflecting the iron dependence of proliferation. Its expression declines with maturation and differentiation. CD71 plays a critical role in cell proliferation by controlling the supply of iron which is essential for many metabolic pathways through the binding and endocytosis of transferrin, the major iron-carrying protein. It may also be involved in signal transduction via its association with the T cell receptor  $\zeta$  chain. The monoclonal antibody RI7217 inhibits cell proliferation *in vitro*.

## **Applications**

FC – Quality tested <sup>1,2,4,5</sup> ICC – Reported in literature <sup>5</sup> IP – Reported in literature <sup>2</sup> WB – Reported in literature <sup>9</sup> Block – Reported in literature <sup>2,3</sup> Sep – Reported in literature <sup>6</sup> Drug Delivery – Reported in literature <sup>7,8</sup>

## **Working Dilutions**

Flow Cytometry	FITC and BIOT conjugates PE conjugate For flow cytometry, the suggested use of these reagents is in a final	$\leq$ 1 µg/10 <sup>6</sup> cells $\leq$ 0.2 µg/10 <sup>6</sup> cells volume of 100 µL	
Other Applications	Since applications vary, you should determine the optimum working appropriate for your specific need.	/ary, you should determine the optimum working dilution for the product that is <sup>•</sup> specific need.	

For Research Use Only. Not for Diagnostic or Therapeutic Use.

# Handling and Storage

- The purified (UNLB) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of borate buffered saline, pH 8.2. No preservatives or amine-containing buffer salts added. Store at 2-8°C.
- The fluorescein (FITC) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The biotin (BIOT) conjugate is supplied as 0.5 mg in 1.0 mL of PBS/NaN<sub>3</sub>. Store at 2-8°C.
- The R-phycoerythrin (PE) conjugate is supplied as 0.1 mg in 1.0 mL of PBS/NaN<sub>3</sub> and a stabilizing agent. Store at 2-8°C. **Do not** freeze!
- The low endotoxin, azide-free (LE/AF) antibody is supplied as 0.5 mg of purified immunoglobulin in 1.0 mL of PBS. Aliquot and store at or below -20°C.
- Protect fluorochrome-conjugated forms from light. Reagents are stable for the period shown on the label if stored as directed.

#### Warning

Some reagents contain sodium azide. Please refer to product specific (M)SDS.

#### References

- 1. Lesley J, Hyman R, Schulte R, Trotter J. Expression of transferrin receptor on murine hematopoietic progenitors. Cell Immunol. 1984;83:14-25. (Immunogen, FC)
- Lesley JF, Schulte RJ. Inhibition of cell growth by monoclonal anti-transferrin receptor antibodies. Mol Cell Biol. 1985;5:1814-21. (FC, IP, Block)
  Kemp JD, Thorson JA, Gomez F, Snith KM, Cowdery JS, Ballas ZK. Inhibition of lymphocyte activation with anti-transferrin receptor Mabs: A
- comparison of three reagents and further studies of their range of effects and mechanism of action. Cell Immunol. 1989;122:218-30. (Block) 4. van der Weyden L, Arends MJ, Rust AG, Poulogiannis G, McIntyre RE, Adams DJ. Increased tumorigenesis associated with loss of the tumor
- van der Weyden L, Arends MJ, Rust AG, Poulogiannis G, McIntyre RE, Adams DJ. Increased tumorigenesis associated with loss of the tumor suppressor gene Cadm1. Mol Cancer. 2012;11:29. (FC)
- 5. Wang J, Wagner-Britz L, Bogdanova A, Ruppenthal S, Wiesen K, Kaiser E, et al. Morphologically homogeneous red blood cells present a heterogeneous response to hormonal stimulation. PloS One. 2013;8(6):e67697. (ICC, FC)
- 6. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Expression of HbC and HbS, but not HbA, results in activation of K-CI cotransport activity in transgenic mouse red cells. Blood. 2004;103:2384-90. (Sep)
- 7. Inoue S, Patil R, Portilla-Arias J, Ding H, Konda B, Espinoza A, et al. Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer. PLoS One. 2012;7(2):e31070. (Drug Delivery)
- 8. Inoue S, Ding H, Portilla-Arias J, Hu J, Konda B, Fujita M, et al. Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res. 2011;71:1454-64. (Drug Delivery)
- 9. Fiani ML, Beitz J, Turvy D, Blum JS, Stahl PD. Regulation of mannose receptor synthesis and turnover in mouse J774 macrophages. J Leukoc Biol. 1998;64:85-91. (WB)